发布求助
文献互助 智能选刊 最新文献

Medical Letter on Drugs and Therapeutics最新文献

筛选
英文 中文
Lodoco: Low-dose colchicine for cardiovascular event prevention. 洛多科：低剂量秋水仙碱预防心血管事件。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-02 DOI: 10.58347/tml.2023.1686b
{"title":"Lodoco: Low-dose colchicine for cardiovascular event prevention.","authors":"","doi":"10.58347/tml.2023.1686b","DOIUrl":"https://doi.org/10.58347/tml.2023.1686b","url":null,"abstract":"Colchicine (Colcrys, and others), which has been available in the US for decades for prophylaxis and treatment of gout flares and other indications in oral formulations that contain 0.6 mg of the drug, has now been approved in 0.5-mg tablets as Lodoco (Agepha) to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple risk factors for cardiovascular disease.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valoctocogene roxaparvovec (Roctavian) - a gene therapy for severe hemophilia A. 缬氨酸roxaparvovec（Roctavian）-一种治疗严重血友病a的基因疗法。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-02 DOI: 10.58347/tml.2023.1686c
{"title":"Valoctocogene roxaparvovec (Roctavian) - a gene therapy for severe hemophilia A.","authors":"","doi":"10.58347/tml.2023.1686c","DOIUrl":"10.58347/tml.2023.1686c","url":null,"abstract":"Valoctocogene roxaparvovec-rvox (Roctavian – Biomarin), an adeno-associated virus (AAV) vector-based gene therapy, has been approved by the FDA for one-time treatment of severe hemophilia A in adults without pre-existing antibodies to AAV serotype 5. It is the first gene therapy to be approved in the US for treatment of hemophilia A.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addendum: Over-the-counter Narcan nasal spray. 附录：非处方Narcan鼻喷雾剂。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-02 DOI: 10.58347/tml.2023.1686f
{"title":"Addendum: Over-the-counter Narcan nasal spray.","authors":"","doi":"10.58347/tml.2023.1686f","DOIUrl":"https://doi.org/10.58347/tml.2023.1686f","url":null,"abstract":"Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone, has become available for sale over the counter (OTC).","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41179320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease. 预防呼吸道合胞病毒疾病的两种疫苗（Arexvy和Abrysvo）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-10-02 DOI: 10.58347/tml.2023.1686a
{"title":"Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.","authors":"","doi":"10.58347/tml.2023.1686a","DOIUrl":"https://doi.org/10.58347/tml.2023.1686a","url":null,"abstract":"Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41180506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nirsevimab (Beyfortus) for prevention of severe RSV disease in young children. Nirsevimab (Beyfortus)用于预防幼儿严重呼吸道合胞病毒疾病。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-18 DOI: 10.58347/tml.2023.1685a
{"title":"Nirsevimab (Beyfortus) for prevention of severe RSV disease in young children.","authors":"","doi":"10.58347/tml.2023.1685a","DOIUrl":"https://doi.org/10.58347/tml.2023.1685a","url":null,"abstract":"The FDA has approved nirsevimab-alip (Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10304558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opill - an OTC oral contraceptive. Opill——一种OTC口服避孕药。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-18 DOI: 10.58347/tml.2023.1685c
{"title":"Opill - an OTC oral contraceptive.","authors":"","doi":"10.58347/tml.2023.1685c","DOIUrl":"https://doi.org/10.58347/tml.2023.1685c","url":null,"abstract":"The FDA has approved Opill (Perrigo), a progestin-only oral contraceptive that contains norgestrel, for sale over the counter (OTC). Opill is the first oral contraceptive to be approved in the US for sale without a prescription. Approval of OTC Opill is intended to increase access to effective contraception and reduce the rate of unintended pregnancies.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10200858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suflave - a low-volume colonoscopy preparation. Suflave -一种小容量结肠镜检查制剂。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-18 DOI: 10.58347/tml.2023.1685b
{"title":"Suflave - a low-volume colonoscopy preparation.","authors":"","doi":"10.58347/tml.2023.1685b","DOIUrl":"https://doi.org/10.58347/tml.2023.1685b","url":null,"abstract":"The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Suflave is marketed as tasting better than other products.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10200859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elranatamab (Elrexfio) for Multiple Myeloma Elranatamab (Elrexfio)治疗多发性骨髓瘤
4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-18 DOI: 10.58347/tml.2023.1685d
{"title":"Elranatamab (Elrexfio) for Multiple Myeloma","authors":"","doi":"10.58347/tml.2023.1685d","DOIUrl":"https://doi.org/10.58347/tml.2023.1685d","url":null,"abstract":"Elranatamab-bcmm (Elrexfio – Pfizer), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135209680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In brief: Melphalan (Hepzato) for uveal melanoma. 简而言之:Melphalan (Hepzato)治疗葡萄膜黑色素瘤。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-04 DOI: 10.58347/tml.2023.1684d
{"title":"In brief: Melphalan (Hepzato) for uveal melanoma.","authors":"","doi":"10.58347/tml.2023.1684d","DOIUrl":"https://doi.org/10.58347/tml.2023.1684d","url":null,"abstract":"The alkylating agent melphalan (Hepzato – Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects <50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10198822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison table: Some drugs for maintenance treatment of opioid use disorder. 比较表:部分阿片类药物使用障碍维持治疗药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-04 DOI: 10.58347/tml.2023.1684b
{"title":"Comparison table: Some drugs for maintenance treatment of opioid use disorder.","authors":"","doi":"10.58347/tml.2023.1684b","DOIUrl":"https://doi.org/10.58347/tml.2023.1684b","url":null,"abstract":"Some Drugs for Maintenance Treatment of Opioid Use Disorder","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10219472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信